Research
Click on a title below to read more or get full articles in pdf format.
Published Journal Articles
Fixed Dose Study on Toxicity, Nova Southeastern University
Results: Under the conditions of the test, no deaths were reported, and all animals were observed to be “bright, alert, and responsive” (BAR). Detailed observation logs and weight logs are provided in the report. Some necropsy findings included mild/moderate mottling of the lungs in some animals, cortical cysts on the kidney in a couple of animals, and the presence of a gavage needle in one animal’s esophagus and stomach at the 9g/kg dose level.
2018 British Journal of Haematology, Toxicity Results
Study Purpose: The study investigated the safety and efficacy of TBL-12 in patients with ASMM.
TBL-12: This is a sea cucumber extract that has shown potential antitumor properties in previous research, including anti-angiogenesis, direct tumor cytotoxicity, and inhibition of osteoclastogenesis.
Participants: Twenty patients with ASMM participated in the study. These patients were characterized as being at high risk for disease progression based on established criteria.
Treatment: Patients ingested 2 units of 20 ml of TBL-12 twice per day, for a total of 80 ml per day.
ONCO: Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature
Glioblastoma is a fatal brain tumor, with recurrence and eventual mortality inevitable despite the current standard of care treatments. The identification of novel therapies capable of extending survival is therefore imperative. In this case series, we describe two cases in
which marine nutraceuticals were used in the management of glioblastoma and conferred a survival benefit exceeding the currently recognized median survival time of standard of care treatment.
In the subsequent literature review, we describe the mechanisms underlying the anticancer and immunogenic properties of marine nutraceuticals, which may contribute to their demonstrated
therapeutic benefit.
Clinical Trials
PMB Announces Partnership With EndBrainCancer.org
Pacific Marine Biotech is pleased to be a Patient Engagement Partner with EndBrainCancer.org (EBCI).
Australia Clinical Trials Update
📣 ANZCTR Clinical Trial Update: IMMUNE‑12 Now Recruiting
We’re pleased to share that the Phase 2 clinical trial of IMMUNE‑12 for high‑grade gliomas (GBM) is actively recruiting participants at multiple sites in Australia…
Interested in Clinical Trial Participation?
Patients, Health Care Professionals and Researchers interested in participating in our clinical trials can contact the clinical trial sites for eligibility criteria and enrollment information.
USA Clinical Trials
We recently updated our projected timeline for US based clinical trials for Investigational Product Immune12 which will be done in association with our ongoing FDA reviews and approvals.
Australia Clinical Trials
PMB announces the provisional approval of our Phase 2 clinical trial aimed at investigating the efficacy of Immune-12 in treating Glioblastoma Multiforme (GBM) in Australia…
Registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) under registration number ACTRN12624001484538p, this trial will involve 60 patients and marks a significant step in our global research efforts… Patient recruitment is now underway…
As we collaborate with esteemed Australian clinical researchers, we are dedicated to developing a robust protocol that leverages local expertise to enhance treatment outcomes for GBM….